This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grau, M. V. Articles by Cole, B. F. Search for Related Content PubMed PubMed Citation Articles by Grau, M. V. Articles by Cole, B. F. Related Collections Epidemiology Epidemiology: Classical Epidemiology

Interaction of Calcium Supplementation and Nonsteroidal Anti-inflammatory Drugs and the Risk of Colorectal Adenomas

Departments of ¹ Community and Family Medicine and ² Medicine, Dartmouth Medical School, Lebanon, New Hamsphire; ³ Department of Medicine, University of North Carolina, Chapel Hill, North Carolina; ⁴ Department of Preventive Medicine, University of Southern California, Los Angeles, California; and ⁵ Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia

Requests for reprints: Maria V. Grau, 46 Centerra Parkway, Suite 300, Lebanon, NH, 03766. Phone: 603-650-3423; Fax: 603-650-3473. E-mail: maria.grau.sepulveda{at}dartmouth.edu

Background: Calcium and aspirin have both been found to be chemopreventive against colorectal neoplasia. However, the joint effect of the two agents has not been well investigated.

Methods: To explore the separate and joint effects of calcium and aspirin/nonsteroidal anti-inflammatory drugs (NSAID), we used data from two large randomized clinical trials among patients with a recent history of colorectal adenomas. In the Calcium Polyp Prevention Study, 930 eligible subjects were randomized to receive placebo or 1,200 mg of elemental calcium daily for 4 years. In the Aspirin/Folate Polyp Prevention Study, 1,121 eligible subjects were assigned to take placebo, 81 mg of aspirin, or 325 mg of aspirin daily for 3 years. In each study, subjects completed a validated food frequency questionnaire at enrollment and were asked periodically about medications and supplements used. Recurrent adenomas and advanced adenomas were the end points considered. We used generalized linear models to assess the separate and combined effects of aspirin (or NSAIDs) and calcium supplementation (or dietary calcium) and the interactions between these exposures.

Results: In the Calcium Trial, subjects randomized to calcium who also were frequent users of NSAIDs had a reduction of risk for advanced adenomas of 65% [adjusted risk ratio (RR), 0.35; 95% confidence interval (95% CI), 0.13-0.96], and there was a highly significant statistical interaction between calcium treatment and frequent NSAID use (P_interaction = 0.01). Similarly, in the Aspirin Trial, 81 mg aspirin and calcium supplement use together conferred a risk reduction of 80% for advanced adenomas (adjusted RR, 0.20; 95% CI, 0.05-0.81); there was a borderline significant statistical interaction between the two treatments (P_interaction = 0.09). In this trial, we found similar trends when we considered baseline dietary calcium intake instead of calcium supplements. For all adenomas considered together, the interactive patterns were not consistent.

Conclusion: Data from two different randomized clinical trials suggest that calcium and NSAIDs may act synergistically to lower the risk of advanced colorectal neoplastic polyps.

This article has been cited by other articles:

				M. E. Martinez and E. T. Jacobs Calcium Supplementation and Prevention of Colorectal Neoplasia: Lessons From Clinical Trials J Natl Cancer Inst, January 17, 2007; 99(2): 99 - 100. [Full Text] [PDF]

				D. Schottenfeld and J. Beebe-Dimmer Alleviating the Burden of Cancer: A Perspective on Advances, Challenges, and Future Directions. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2049 - 2055. [Abstract] [Full Text] [PDF]